The recent finding that CD38-driven NAD+ depletion in endometrial macrophages is pathological, not adaptive, presents a paradox: why would a conserved NAD+-consuming enzyme like CD38 be upregulated in an age-dependent manner within a tissue critical for reproduction, if its effect is purely damaging? The hypothesis is that this represents a maladaptive evolutionary mismatch. Ancestrally, modest CD38 upregulation and localized NAD+ scarcity in the uterine immune niche may have served as a scarcity signal, reprogramming tissue-resident macrophages to prioritize structural integrity and immune surveillance over the high-energy demands of decidualization—effectively a "reproductive timeout" during periods of systemic metabolic stress (e.g., infection, poor nutrition). In the context of modern lifespan extension, this transient adaptive signal becomes chronic and pathological, driving the stromal senescence and fibrosis observed in aging endometria.

Mechanistic Extension: The NAD+/α-Ketoglutarate (α-KG) Axis in Macrophage-Fibroblast Crosstalk We propose that the NAD+ depletion in macrophages does more than reduce ATP; it epigenetically locks these cells into a pro-fibrotic, pro-senescent state via disruption of the NAD+-dependent sirtuin/α-KG/ten-eleven translocation (TET) enzyme axis. NAD+ is a required co-factor for sirtuins, which deacetylate and activate enzymes like isocitrate dehydrogenase (IDH) that produce α-KG. α-KG is both a mitochondrial metabolite and an essential co-factor for TET demethylases and Jumonji-domain histone demethylases, which maintain open, youthful chromatin states. As NAD+ falls in aged endometrial macrophages, α-KG production likely plummets, leading to DNA and histone hypermethylation that silences reparative gene programs and locks in a senescence-associated secretory phenotype (SASP).

This reprogrammed macrophage then directly signals to stromal fibroblasts via two putative mechanisms:

1. Exosomal Transfer of Damage: Aged, NAD+-depleted macrophages may package SASP factors (IL-6, TGF-β) and damaged miRNAs into exosomes, which directly induce paracrine senescence and collagen deposition in stromal cells, explaining the fibrosis that persists even after NMN supplementation rescues stromal NAD+ levels [https://pmc.ncbi.nlm.nih.gov/articles/PMC12745663/].
2. Metabolic Competition: These macrophages may become hyper-glycolytic and lactogenic (a common consequence of NAD+ deficiency), creating a local acidic, hypoxic niche that further stresses stromal mitochondria and impairs their decidualization capacity, independent of their own NAD+ status.

Testable Predictions & Falsifiability This model generates clear, testable hypotheses:

1. Spatial Metabolomics: The lowest NAD+/NADH ratios in aged endometria should localize specifically to CD163+ or CD206+ tissue-resident macrophage clusters, not uniformly across stromal cells.
2. The α-KG Rescue Experiment: Supplementation with cell-permeable α-KG (or an α-KG precursor like dimethyl-α-KG) in aged endometrial macrophage-stromal co-cultures should outperform NMN supplementation alone in restoring decidualization markers (IGFBP1, PRL) and reducing fibrosis, by bypassing the NAD+ bottleneck to directly reset the epigenetic landscape. A failure to observe this would falsify the centrality of the NAD+/α-KG axis.
3. Conditional Knockout: Floxing Cd38 specifically in Cx3cr1+ (macrophage-lineage) cells in aged mice should prevent endometrial NAD+ decline, reduce fibrosis, and improve fertility more effectively than systemic NMN treatment, proving the niche-specific, immune-driven causality.

Conclusion The endometrial aging phenotype is not the body "downgrading its ambitions" in a coordinated manner, but the catastrophic result of an ancient immune-metabolic safeguard—macrophage CD38 activity—being chronically activated. The initial signal may have been adaptive, but the outcome is pure damage: a NAD+ crash in a critical cellular niche that epigenetically corrupts local immune function, which in turn propagates senescence to the stroma. The incomplete rescue by NMN [https://pmc.ncbi.nlm.nih.gov/articles/PMC12745663/] underscores that we must target the upstream, niche-specific immune reprogramming, not just the downstream metabolite.